首页|期刊导航|肿瘤预防与治疗|CA125值对PARPi一线维持治疗的卵巢癌患者进展风险的预测价值:一项真实世界临床研究

CA125值对PARPi一线维持治疗的卵巢癌患者进展风险的预测价值:一项真实世界临床研究OA

Predictive Value of CA125 for Progression Risk in Ovarian Cancer Pa-tients Receiving First-Line Maintenance Therapy with PARP Inhibitors:A Real-World Clinical Study

中文摘要英文摘要

目的:分析血清癌抗原125(cancer antigen 125,CA125)预测聚腺苷二磷酸核糖聚合酶抑制剂[poly(ADP-ri-bose)polymerase inhibitor,PARPi]一线维持治疗的卵巢癌患者的疾病进展风险的价值,探索新诊疗模式下更优的预警标准和随访策略.方法:收集2015 年1 月至2025 年3 月四川省肿瘤医院收治的初治晚期卵巢癌患者的临床病理资料及随访资料,根据是否接受 PARPi 一线维持治疗分为 PARPi 维持组和未维持组,其中 PARPi 维持组纳入起始时间为 2018 年 8 月.基于国际妇科肿瘤协作组(Gynecologic Cancer InterGroup,GCIG)生化进展标准(生化进展)与实体瘤疗效评价标准 1.1 版(影像学进展)评价两组患者的疾病进展情况,并采用 ROC 曲线进一步探索分析更优的CA125 预警截断值.结果:共纳入448 例患者,PARPi 维持组309 例,未维持组139 例.PARPi 维持组的中位无进展生存时间较未维持组明显延长(33.4 个月 vs 16.5 个月,P<0.001).PARPi 维持组生化进展 89 例(28.8%),影像学进展 149 例(48.2%);未维持组分别为 84 例(60.4%)和 127 例(91.4%).部分影像学进展患者的 CA125 并未达到生化进展标准(假阴性率),PARPi 维持组和未维持组分别为 44.3%和 39.9%(P>0.05);其中,PARPi 维持组有42 例(28.2%)影像学进展的患者 CA125 值仍在正常范围(<35 U/mL),未维持组有 25 例(19.7%)(P>0.05).在PARPi 维持组与未维持组,CA125 预测疾病进展的灵敏度分别为 55.8%和 65.4%,Youden 指数分别为 0.52 和 0.57(P>0.05),预测效能较差.PARPi 维持组的 ROC 曲线分析结果显示,CA125 最低值的 2 倍可作为预测疾病进展的新截断值,其灵敏度为 85.2%,特异度为89.4%,假阴性率为14.8%,Youden 指数为0.75.结论:在卵巢癌维持治疗时代,GCIG 生化进展标准预测疾病进展的灵敏度有所下降,应更加重视随访中的定期影像学检查.采用 CA125 2×最低值为新的生化进展标准可明显降低假阴性率,提高预测疾病进展的效能,指导及时完善影像学检查,避免病情延误.

Objective:This study aims to analyze the value of serum carbohydrate antigen 125(CA125)in predicting the risk of disease progression in ovarian cancer patients receiving first-line maintenance therapy with poly(ADP-ribose)poly-merase inhibitors(PARPi),and to explore optimized early warning criteria and follow-up strategies under a new treatment paradigm.Methods:Clinicopathological and follow-up data of patients with newly diagnosed advanced ovarian cancer admit-ted to Sichuan Cancer Hospital between January 2015 and March 2025 were collected,and the patients were divided into a PARPi maintenance group(with enrollment commencing in August 2018)and a non-maintenance group based on whether they received first-line PARPi maintenance therapy.Disease progression in the two groups was assessed based on the Gyne-cologic Cancer InterGroup(GCIG)biochemical progression criteria and the Response Evaluation Criteria in Solid Tumors version 1.1.ROC curve analysis was performed to identify an optimized CA125 cut-off value for predicting disease progres-sion.Results:A total of 448 patients were enrolled,including 309 in the PARPi maintenance group and 139 in the non-ma-intenance group.Median progression-free survival was significantly prolonged in the PARPi maintenance group compared with the non-maintenance group(33.4 months vs 16.5 months,P<0.001).In the PARPi maintenance group,89 patients(28.8%)experienced biochemical progression and 149(48.2%)experienced radiologic progression;the corresponding numbers in the non-maintenance group were 84(60.4%)and 127(91.4%),respectively.A proportion of patients with ra-diologic progression did not meet the CA125 biochemical progression criteria(false negatives),with false-negative rates of 44.3%in the PARPi maintenance group and 39.9%in the non-maintenance group(P>0.05).Among these,42 patients(28.2%)in the PARPi maintenance group and 25(19.7%)in the non-maintenance group had CA125 levels within the normal range(<35 U/mL)(P>0.05).The sensitivity of CA125 for predicting ovarian cancer progression was 55.8%in the PARPi maintenance group and 65.4%in the non-maintenance group,with Youden indices of 0.52 and 0.57,respectively(P>0.05),indicating poor predictive efficacy.For the PARPi maintenance group,ROC curve analysis identified two times the nadir CA125 level as a new cut-off value for predicting disease progression,yielding a sensitivity of 85.2%,specificity of 89.4%,false negative rate of 14.8%,and Youden index of 0.75.Conclusion:In the era of maintenance therapy for ovarian cancer,the sensitivity of GCIG biochemical progression criteria for predicting disease progression has declined,underscoring the necessity of scheduled radiographic surveillance in follow-up.Using a CA125 level of 2×nadir as the new criterion for bio-chemical progression can significantly reduce the false negative rate,improve the efficacy of predicting disease progression,and guide the timely implementation of radiographic examinations,thereby preventing delays in diagnosis and treatment.

姚红;裴姣;张国楠;李婷媛;郑静;黄小荞;刘红;王登凤

611137 成都,成都中医药大学 医学与生命科学学院||644600 四川 宜宾,宜宾市第一人民医院 妇科||610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 妇瘤科610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 临床研究部610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 妇瘤科610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 实验研究部610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 妇瘤科610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 妇瘤科610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 妇瘤科610041 成都,四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院 妇瘤科

医药卫生

卵巢癌维持治疗复发监测癌抗原125预测效能

Ovarian cancerMaintenance therapyRecurrence monitoringCancer antigen 125Predictive efficacy

《肿瘤预防与治疗》 2026 (9)

725-733,9

国家医学高次人才计划(编号:国卫人发[2024]26 号)2024年度电子科技大学医学院临床医学学科发展基金项目(编号:YXYLCJJ202403006) This study was supported by National Medical High-Level Talent Program(No.NHCO[2024]No.26),and by grants from University of Electronic Science and Technology of China(No.YXYLCJJ202403006).

10.3969/j.issn.1674-0904.2026.09.001

评论